Trial finds oral iron drug safe, effective for treating anemia in kidney disease patients

In a phase 3 trial of patients with chronic kidney disease, 52.1% of patients receiving oral ferric citrate experienced a significant boost in hemoglobin levels (a reflection of red blood cell counts) compared with 19.1% of patients receiving placebo. A treatment effect was seen as early as 1-2 weeks after the start of treatment, and the response was durable….

In a phase 3 trial of patients with chronic kidney disease, 52.1% of patients receiving oral ferric citrate experienced a significant boost in hemoglobin levels (a reflection of red blood cell counts) compared with 19.1% of patients receiving placebo. A treatment effect was seen as early as 1-2 weeks after the start of treatment, and the response was durable….